We studied the use of autologous bone marrow transplantation (ABMT) as treatment for acute myeloid leukemia (AML) in adults up to age 60. We used a preparative regimen of busulfan 16 mg/kg plus etoposide 60 mg/kg and bone marrow purged with 100 g/ml of 4-hydroperoxycyclophosphamide (4HC). We treated 50 first remission patients; there were two treatmentrelated deaths and 13 relapses. With median follow-up of 6.8 years (minimum 4.5) disease-free survival (DFS) is 70%, relapse rate 27% and overall survival 72%. Patients with favorable cytogenetics had DFS 78% and relapse 18% whereas unfavorable patients had DFS 63% and relapse rate 35%. For 25 patients in second or third remission there were five treatment-related deaths and seven relapses. DFS is 52% and relapse rate 35%. None of six patients with primary refractory AML had long-term disease control. These data support the use of ABMT with an intensive preparative regimen and purged bone marrow as a highly effective treatment for adults with AML. Keywords: ABMT; AML; 4HC During the past decade there have been a number of improvements in the treatment of young adults with acute myeloid leukemia. All-trans retinoic acid (ATRA) has been identified as an important new agent in the treatment of acute promyelocytic leukemia.
rate and improve disease-free survival (DFS) for young adults with AML. 4 Furthermore, studies comparing preparative regimens have demonstrated the principle that more intensive preparative regimens can lower the relapse rate. 5 However, in the allogeneic transplant setting, these improvements in disease control have been offset by increases in treatment-related mortality (TRM). The use of targeted radiation through radioimmunoconjugates has produced very promising results and may allow this impasse to be broken. 6 Although allogeneic transplantation consistently produces improved DFS when compared to conventional chemotherapy, this treatment is limited by donor availability and by the 25% TRM which raises the question as to whether reserving allogeneic transplant as a salvage therapy would be an equal or better strategy.
Autologous bone marrow transplantation (ABMT) has been actively investigated as an alternative way to improve outcome for AML patients. The treatment is attractive because of the potential for broad use in adults up to and perhaps beyond age 60 and because of relatively low TRM. Because of the absence of graft-versus-host disease and confounding immunosuppression autologous BMT provides a setting in which dose intensity of the preparative regimen may be explored with better safety than in the allogeneic setting. However, at this time the role of autologous BMT in the treatment of adult AML in first remission remains controversial. A large prospective randomized study from Europe demonstrated improved DFS when compared to conventional chemotherapy but failed to show improvement in overall survival. 7 Preliminary results of a US intergroup trial showed no overall improvement in DFS for autologous transplantation compared to high-dose Ara-C chemotherapy. 8 However, only 60% of patients randomized to the ABMT arm received the intended therapy, a much lower percentage than in the other arms and possibly compromising the potential to demonstrate a beneficial effect.
In 1993, we reported the preliminary results of a trial of ABMT using 4-hydroperoxycyclophosphamide (4HC)-purged bone marrow and an intensive preparative regimen combining busulfan and etoposide. 9 At the time of that report accrual was ongoing and follow-up was short. We now report the mature results of the completed trial with 50 first remission and 25 second/third remission patients. With median follow-up of 6.8 years and minimum followup of 4.5 years we confirm our initial promising results with disease-free survival of 70% in first remission patients and 52% in subsequent remission patients.
Materials and methods

Patients
Patients were treated between October 1986 and March 1993. Patients in first remission were required to have de novo AML and those with prior myelodysplasia, myeloproliferative diseases, or treatment-associated leukemia were excluded. Remission was defined by normal bone marrow morphology with Ͻ5% blasts, resolution of abnormal cytogenetics, neutrophils greater than 1500/l, and platelets greater than 140 000/l. In addition, remissions were required to last for a minimum of 30 days. We required adequate organ function with bilirubin less than 1.5 mg/dl and aspartate transaminase (AST) and alkaline phosphatase less than twice the upper limit of normal. For patients with more advanced disease, eligibility criteria were similar. Neutrophils were required to be more than 1000/l and platelets greater than 100 000/l. Remissions were not required to last 30 days and the AST and alkaline phosphatase could be up to three times the upper limit of normal. Six patients were designated as 'primary refractory' if they had failed to achieve complete remission with at least 6 days (12 doses) of high-dose Ara-C plus an anthracycline (usually daunorubicin 180 mg/m 2 over 3 days). They were eligible for transplant if they achieved remission with salvage chemotherapy. All patients gave written informed consent using forms approved by the Committee on Human Research to the University of California San Francisco or Alta Bates Medical Center in accordance with the Helsinki Declaration. For purposes of outcome analysis, first remission patients were divided into risk groups based on cytogenetics. Favorable patients had t(8;21), t(15;17) or inv 16q, and others lacking these features or not studied were considered unfavorable. Since only one first remission patient had 'poor-risk' cytogenetics, this patient was included in the unfavorable group.
Bone marrow collection and processing
Bone marrow (BM) was harvested and processed as previously described. All patients transplanted in second or third remission had BM harvested during that same remission. The buffy coat was separated by centrifugation and prepared at a cell concentration of 2 × 10 7 /ml in M199 media (GIBCO, Grand Island, NY, USA) and 20% autologous plasma and the hematocrit was adjusted to between 5 and 10%. 4-HC (Nova Corporation, Baltimore, MD, USA) was added to the cell suspension to obtain a final concentration of 100 g/ml. Cells were incubated with 4-HC at 37°C for 30 min, and were then rapidly cooled to 4°C. Cells were washed and re-suspended for freezing in M199 media to achieve a final cell concentration of 4 × 10 7 /ml in 5% autologous plasma and 10% dimethyl sulfoxide (DMSO) and were frozen at a controlled rate. At the time of autologous reinfusion, each bag was thawed in a 37°C water bath and immediately infused intravenously (i.v.). The median cell dose was at 2.4 × 10 8 nucleated cells/kg (1.3-5.7).
Preparative chemotherapy
Busulfan (1 mg/kg) was administered orally every 6 h for 4 days (total dose 16 mg/kg) on days Ϫ7 to Ϫ4. Etoposide (60 mg/kg) was administered by i.v. infusion over 6-10 h on day Ϫ3. Etoposide was mixed at a concentration of 0.6 mg/ml in normal saline and infused at a rate of 1 l/h. The first 31 patients (16 in first remission and 15 in subsequent remission) were dosed based on actual body weight. Twenty-seven subsequent patients (16 in first remission and 11 in subsequent remission) were dosed based on the mean of ideal and actual body weight. The final 23 patients (18 first remission and five subsequent remission) were dosed based on a corrected weight calculated as ideal weight plus 25% of the difference between actual and ideal weight. BM was thawed and infused on day 0.
Supportive care
Patients were hospitalized in private rooms with high efficiency particle (HEPA) air filtration. Acyclovir (5 mg/kg) administered every 8 h was begun intravenously on day Ϫ2 and continued until hospital discharge, at which point patients received 200 mg orally three times a day until 1 year after transplant. Trimethoprim/sulfamethoxysol (1 double-strength tablet p.o. twice a day) was administered on weekends throughout hospitalization and until at least 3 months post-transplant or until the CD4 lymphocyte count exceeded 200/l. Gammaglobulin (500 mg/kg) was administered i.v. every 3 weeks for four doses beginning on day Ϫ1. Amphotericin (0.3 mg/kg) was begun on day +1. Broad-spectrum antibiotics, most commonly a combination of ceftazidime and vancomycin, were begun prophylactically when the neutrophil count fell to less than 500/l. Platelets were transfused to maintain a platelet count greater than 20 000/l.
Toxicity grading
Toxicity was graded using the UCSF BMT Toxicity Grading Scale. Mucositis was scored as grade 2 (moderate) if the patient required analgesics or was unable to eat due to mucositis and grade 3 (severe) as Ͼ25% if the mucosa was ulcerated. Skin toxicity was scored as grade 2 (moderate) if the patient required narcotic analgesia and/or local care including emollients and wrapping and grade 3 (severe) if significant skin breakdown occurred.
Statistical evaluation
Remission, DFS, and survival were all calculated from the date of BMT and were calculated using Kaplan-Meier analysis on a Macintosh computer. In calculating DFS, both relapses and treatment-related deaths were considered as adverse events, but one unrelated death was censored. Overall survival is calculated based on all deaths. DFS and survival are expressed as Ϯ twice the standard error of the mean to yield boundaries of 95% confidence intervals. Data were analyzed as of 10 October 1997.
Results
Patients
Fifty patients were treated in first remission ( Table 1 ). The median age was 37 years and five patients were over 50. Forty-three of the patients received their induction chemotherapy at the University of California San Francisco with a combination of HDAC and either daunorubicin, mitoxantrone or idarubicin. One patient was treated at UCSF with standard-dose Ara-C plus daunorubicin during pregnancy and six patients were referred from outside institutions after standard-dose Ara-C induction chemotherapy. In almost all instances patients were taken directly from a single course of induction chemotherapy to transplantation; three patients received a single course of post-remission therapy with standard-dose Ara-C prior to transplantation. Patients proceeded from remission to transplantation in a median of 3.0 months (range 1.0-10 months), four patients beyond 4.5 months and only one patient after an interval of more than 6 months. Twenty-three patients had favorable cytogenetics at initial diagnosis and their median age was 29 years. Thirteen patients had FAB M3 and all patients tested had t(15;17); two of these patients also had trisomy 8. Four of these patients presented with initial white blood counts greater than 10 000/l. None of these M3 patients received ATRA. Three patients had t(8;21) and all had FAB type M2. Seven patients had FAB M4 Eo with inversion 16q. Twenty-seven patients (median age 40) had unfavorable cytogenetics, one of whom had poor-risk feature with FAB M0 and complex cytogenetic abnormalities.
Thirty-one patients with more advanced disease were treated, 23 in second and two in third remission. The median age was 35 and three of these patients were over age 50. The median length of their first remission was 8 months and only one patient had an initial remission longer than 2 years. On achieving remission, these patients proceeded rapidly to transplantation (median 2 months, range 1-8) and only one patient was transplanted after a second remission interval longer than 6 months. None of these 
Prior post-remission therapy 3 0 (6%) patients received post-remission therapy prior to transplantation. Fourteen (56%) of these 25 second and third remission patients had received HDAC before relapsing. Four of these patients had favorable cytogenetics. One patient had M4 Eo with inversion of 16q and had relapsed after standard-dose therapy. Three patients had t(8;21). All had relapsed in less than 1 year and two of these three patients had received prior HDAC. Two patients had poorrisk cytogenetics, one with monosomy 7 and one with t(9;11) secondary to etoposide-containing chemotherapy given for a previous diagnosis of acute lymphoblastic leukemia. In addition to these 25 CR2/3 patients we treated six 'primary refractory' patients because they had failed primary induction chemotherapy with HDAC plus either daunorubicin or mitoxantrone; one had t(15;17).
Treatment results
Of 50 patients in first remission, there were two treatmentrelated deaths and one death unrelated to either treatment or leukemia. Thirteen patients relapsed and 34 remain in continuous remission. With median follow-up of 6.8 years (4.5-10.9) disease-free survival is 70 Ϯ 12% (95% confidence intervals) and relapse rate 27 Ϯ 12% (Figure 1 ). Overall survival is 72 Ϯ 12% (Figure 2 ). Most adverse events occurred early and the median time to relapse was 10 months (5.5-23.5). Only four relapses occurred after 1 year.
Of the 23 patients with favorable cytogenetics there was one treatment-related death and four relapses. With median follow-up of 7.1 years, disease-free survival is 78 Ϯ 16% and relapse rate 18 Ϯ 16% (Figure 3) . Of the 27 patients with unfavorable cytogenetics there was one treatmentrelated death, one unrelated death and nine relapses. In this group, the patient with FAB M0 and high-risk cytogenetics has remained in remission. With median follow-up of 5.9 years disease-free survival is 63 Ϯ 18% and relapse rate 35 Ϯ 18% (Figure 4) .
Of the 13 patients who relapsed, five received reinduction therapy and three entered second remission. One patient was treated with a second autologous bone marrow transplantation using 4HC-purged bone marrow (harvested in second remission) and a TBI/cyclosphosphamide/ etoposide preparatory regimen and remains well 8.4 years later. Five patients underwent allogeneic transplantation (three siblings and two unrelated donors) and one patient remains alive and well 3.1 years later. Of the 25 second and third remission patients there were five treatment-related deaths and seven relapses, and 13 patients remain in continuous remission. With median follow-up of 7.1 years (4.5-9.9) disease-free survival is 52 Ϯ 20% and the relapse rate 35 Ϯ 20% ( Figure 5 ). The median time to relapse was 4 months (3-37) and only one relapse occurred later than 1 year.
Of the second and third remission patients all four patients with favorable cytogenetics became long-term survivors as did nine of the 19 standard-risk patients. Both of the patients with high-risk cytogenetics relapsed. Similarly, the primary induction failure group fared poorly with four treatment-related deaths and two relapses. 
Toxicity
First remission patients: Engraftment was slow ( Table 2) . Four of the 48 survivors took longer than 60 days to achieve an absolute neutrophil count (ANC) greater than 500/l. Platelet transfusion support was required for a median of 52 days (18-534) and platelets reached levels of 50 000 and 100 000/l at 84 and 170 days, respectively. The median number of platelet transfusions given was 23 , and four of the 34 (12%) long-term survivors required platelet transfusion support for longer than 6 months. The median number of units of red blood cells transfused was 11 (0-30) and six patients (18%) required red blood cell transfusion support for longer than 6 months. Patients were hospitalized for a median of 41 days (25-77) after bone marrow infusion on day 0. Non-hematologic toxicity affected primarily mucosa, skin and gastrointestinal tract. Patients received parenteral nutrition for a median of 38 days and narcotic analgesics for a median of 19 days. Forty-nine of 50 (98%) patients experienced grade у2 (moderate or severe) mucositis. This lasted for a median of 10 days, and 11 patients (22%) had moderate or severe mucositis for longer than 14 days. Skin toxicity was often pronounced with painful desquamative dermatitis affecting primarily the palms, soles, axilla and perineum. Sixty percent of patients experienced grade у2 (moderate or severe) skin toxicity and this lasted for a median of 4 days. Ten patients (20%) had significant skin toxicity lasting longer than 14 days. Hepatic toxicity was not a major problem. The median peak bilirubin was 1.8 mg/dl and only two patients had peak bilirubins greater than 6 mg/dl. There were two treatment-related deaths. One (day +97) was due to diffuse gut injury and this occurred in a patient whose chemotherapy dosage was based on actual body weight which was 15% greater than ideal body weight. The other death (day +34) was related to sepsis and subsequent respiratory failure.
Subsequent remission patients:
Compared to first remission patients, neutrophil recovery was similar (Table  2) . Platelet recovery was more delayed with platelet transfusion support required for an additional month, and many patients never reached normal platelet counts. Two of the 13 long-term survivors required platelet support for greater than 6 months. RBC transfusions were required for a median of 64 days and two patients required RBC transfusion support for longer than 6 months.
Patients were hospitalized for a median of 39 (26-62) days after bone marrow infusion. Mucosal and skin toxicity were similar to those seen in first remission patients. Ninety-seven percent of the patients experienced mucositis grade у2 and this lasted for a median of 9 days. Five patients (16%) had moderate or severe mucositis for longer than 14 days. Parenteral nutrition was required for 31 days and narcotic analgesics for 22 days. Moderate or severe skin toxicity was seen in 74% of patients. This lasted a median of 7 days and lasted longer than 14 days in seven patients (23%). Hepatotoxicity was more significant than in first remission patients. The median peak bilirubin was 2.2 mg/dl. However, five patients had peak bilirubins greater than 6 mg/dl and fatal veno-occlusive disease occurred in three patients.
There were nine treatment-related deaths (days +28, 29, 37, 68, 90, 91, 104, 130, 186), four in the primary refractory patients and five in subsequent remission patients. Two primary refractory patients died of graft failure and two others died of aspergillus pneumonia and resistant herpes simplex pneumonia. In the CR2/3 group there were three deaths from veno-occlusive disease and one each from CMV pneumonia and disseminated fusarium infection.
Discussion
The results of this completed trial confirm our original report of excellent outcome for patients treated with this program. For 50 patients treated in first remission, diseasefree survival is 70% with a relapse rate of 27%. With minimum follow-up of 4.5 years and the last relapse occurring at less than 2 years, the results are very unlikely to change and a stable plateau has been established.
Our intent was to treat these patients early in the course of their disease so that high-risk patients would be able to receive the potential benefits of this treatment before experiencing early relapse. Our patients were transplanted early in the course of their disease (median 3 months) and only one patient was transplanted after a first remission of longer than 6 months. Most patients had no post-remission chemotherapy prior to entering this treatment program and only three patients received a single course of standarddose Ara-C-based treatment. Therefore, our results are not due to either prior intensive post-remission chemotherapy or to prolonged delay. Although our intent was to treat unselected patients we cannot rule out an element of selection bias. At UCSF, this program was the treatment of first choice and 70% of all AML patients (age Ͻ60) in first remission were treated on this study. Patients were also referred from outside institutions and we are unable to comment on possible selection bias for these patients.
Our results need to be interpreted in the context of the patients enrolled in this study. Cytogenetics has emerged as the single most important prognostic factor for adults under age 60 with AML in first remission. Forty-six percent of our first remission patients had favorable cytogenetics and hence these favorable patients are over-represented. As expected, their median age of 29 is younger than that of the overall group. For these favorable patients the longterm prognosis was excellent, with disease-free survival of 78% and a relapse rate of only 18%. We also treated four patients with favorable cytogenetics in second remission and all remain in remission. Thus this ABMT program appears extremely effective in favorable patients. However, non-ablative options for favorable patients appear to be improving, most notably treatment with ATRA plus chemotherapy for t(15;17) patients with low white blood cell counts; 10 there is also evidence that HDAC improves outcome for patients with t(8;21) and inv 16q, although this remains to be confirmed. 3, [11] [12] [13] At this time, the optimal treatment strategy for patients with favorable cytogenetics remains to be established. Since prognostic factors that predict for success with one type of therapy often predict success with other therapies, it is possible that ABMT will provide an advantage over conventional chemotherapy despite good results with the latter.
Our treatment results are most significant in the patients lacking favorable cytogenetics. The DFS of 63% with relapse rate of 35% are far superior from that expected with conventional chemotherapy including HDAC. Our results in CR2/3 patients appear to confirm these results, with DFS of 52% and a relapse rate of 35%. These subsequent remission patients are not subject to the kind of selection bias that may be operative in first remission. Lacking a suitable allogeneic donor, these patients have no other potentially curative options. Length of first remission has been reported to be the most significant prognostic factor for second remission patients. 14 The median first remission duration in our patient group was 8 months and only one patient had a remission of over 2 years. These patients went rapidly from achieving second remission to the transplant and no patient received post-remission therapy prior to entering our treatment program. Four of these patients had favorable cytogenetics (although the fact that they relapsed argues against classifying them as favorable). For the remaining 21 unfavorable patients long-term disease-free survival is 43%.
Our treatment program was not effective in patients with very high-risk features. There were no long-term survivors in the six patients who initially failed to achieve remission after HDAC-based induction regimens, and both CR2 patients with high-risk cytogenetics relapsed. Only one first remission patient had high-risk cytogenetic features, and this patient did well. We do not have enough data to comment on the efficacy of this program for high-risk cytogenetic patients or for patients with underlying myelodysplasia (who were excluded). However, allogeneic transplantation has produced DFS in only 24% of first remission patients with high-risk cytogenetics and improved treatments are needed. 15 We used an intensive preparative regimen in an attempt to reduce the relapse rate. Since syngeneic transplantation is associated with a 50% relapse rate in first remission AML patients when standard preparative regimens are used, 16 one would expect the relapse rate to be at least this high in autologous transplantation unless an as yet uncharacterized immune modulation contributes to the overall success of ABMT programs. Our regimen was toxic with significant mucosal and skin toxicity that exceeds that seen with standard regimens. However, these toxicities were reversible and our overall treatment-related mortality (TRM) was low despite the added factor of markedly delayed engraftment. This low TRM may be due to the considerable supportive efforts expended in this single institution study and it is likely that the mortality rate would be higher with generalized use of this program. Some of the excess skin and mucosal toxicity was due to the initial calculation of chemotherapy dosage based on actual weight. As previously reported, we found that excessive toxicity was seen in patients who received a dose greater than 15% of the ideal body weight dose. Based on these findings we now dose based on a corrected weight calculated as ideal weight plus 25% of the difference between actual and ideal and this appears to have reduced toxicity.
Mucosal toxicity was significant with almost all patients experiencing moderate or severe mucositis and with this level of mucositis lasting for greater than 2 weeks in approximately 20% of patients. Skin toxicity was moderate or severe in 66% of patients and in 21% of cases this lasted longer than 14 days. These levels of non-hematologic toxicity may be prohibitive for general use of this program. However, we have used the identical preparative regimen with peripheral blood stem cell (PBSC) transplantation in 90 patients and have seen marked reduction in these toxicities. 17 Only 1% of patients had mucositis or skin toxicity longer than 2 weeks, and no patient had severe skin toxicity longer than 3 days. Some of the amelioration of toxicity may be due to the rapid engraftment with PBSC since we now see an ANC Ͼ1000/l on day +9. Other than rapid engraftment there have been no changes in supportive care that would have reduced the risk of mucositis, and the only change that could have possibly reduced skin toxicity was a decision to have patients shower twice daily during the administration of chemotherapy based on the hypothesis that chemotherapy excreted in sweat may have contributed to skin toxicity. With this reduction in non-hematologic toxicity and the shortening of median hospital discharge to day +15 this busulfan/etoposide regimen no longer appears overly toxic when used in the context of PBSC and is amenable to generalized use.
Our decision to purge bone marrow in vitro with 4HC was based on our concern of reinfusion of viable clonogenic leukemic cells. Despite encouraging data in single arm studies, the benefit of in vitro marrow purging in ABMT for AML remains unproven. However, the use of 4HC marrow purging certainly has a disadvantage with a significant delay in engraftment. This results in prolonged hospitalization, resource utilization and expense. In addition, a significant minority of patients requires markedly prolonged transfusion support with red blood cells and platelets subjecting them to risks of transfusion-associated disease as well as a risk of fatal hemorrhage. Prior marrowinjuring therapy appears to contribute to the risk of delayed engraftment with 4HC-purged bone marrow. We have reported that patients receiving mitoxantrone combined with HDAC as remission induction therapy had an increased risk of delayed engraftment compared to patients receiving daunorubicin plus HDAC. 18 Others have reported cumulative prior chemotherapy as a risk factor for slow engraftment with mafosfamide purged marrow. 19 A high percentage of patients treated in this study had received prior therapy including HDAC, and this may have influenced our results in a number of ways. Prior HDAC may have contributed to delayed engraftment. Stein et al 20 reported engraftment data which are similar to ours using unpurged bone marrow collected after post-remission therapy including HDAC. Alternatively, the use of HDAC remission induction therapy may have had a beneficial effect. We chose to use HDAC induction therapy in order to maximize initial cytoreduction as part of an overall treatment plan comprised of only two steps. The use of HDAC induction therapy has not increased initial remission rates (compared to standard-dose Ara-C regimens) but has been reported to prolong remission duration, most likely because of greater initial cytoreduction. 21, 22 To date, there has been little long-term toxicity from our ABMT program. We have not seen any cases of myelodysplasia or late infection. There has been one late secondary malignancy, diffuse large cell non-Hodgkin's lymphoma (in a patient with initial FAB M5) occurring at 7 years. One disadvantage of the early application of ABMT is that it is difficult to salvage patients after relapse. Of the 13 first remission patients who relapsed, only two became longterm survivors.
The role of ABMT in AML remains under study. It appears to be the treatment of choice for patients in second remission and long-term DFS greater than 30% are consistently reported. 14, [23] [24] [25] [26] [27] These results appear similar to those generated by allogeneic transplantation. 28 Although the relative merits of autologous and allogeneic transplantation in this setting could be debated, transplantation certainly appears markedly superior to conventional chemotherapy which has little to offer in this setting. For first remission patients the role of ABMT is harder to define and will require further study. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] 
